drugset / Trial / NCT07239973

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

NCT07239973

Phase 1 Recruiting 75 enrolled BrightGene Bio-Medical Technology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.

Timeline

Start
2025-10-21
Primary completion
2026-03-31
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown Oral

Indications

No indication recorded.